Brepocitinib Overview & RVT-3101 Update
Anti-FcRn Franchise Overview
+
$2
Batoclimab
༤༥༽. ༩༦
+
+
+
+
IMVT-1402
༽༩
+
+
+
+
+
roivant
1. Potential outcomes if Phase 1 results are as predicted by pre-clinical studies in cynomolgus monkeys
Tailored dosing to address varying symptom severity across
indications and stage of disease
Short term maximal IgG suppression
• Lower chronic doses where less IgG suppression needed
•
Fixed duration dosing in certain conditions
Multiple pivotal trials ongoing in MG, TED and CIDP
Chronic dosing to address symptom severity and
duration for extended periods of time (>12 weeks)1
•
•
Sustained maximal IgG suppression where needed
Chronic delivery with simple subcutaneous delivery in seconds
No or minimal impact to albumin / LDL
Pivotal-enabling catalyst in 2023: IMVT-1402 initial
Phase 1 data expected in mid-2023
22
22
For investor audiences onlyView entire presentation